Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) operates as a fully-integrated biopharmaceutical company focused on developing and commercializing innovative therapies for central nervous system disorders, immunology, infectious diseases, and rare diseases. The company's website is www.tonixpharma.com.

Tonix maintains a diversified portfolio spanning commercial, development, and discovery-stage programs. The company's commercial platform includes TONMYA, a centrally acting non-opioid analgesic approved by the FDA in August 2025 for treating fibromyalgia in adults and launched in November 2025, representing Tonix's first internally developed product to achieve FDA approval. TONMYA is the first new fibromyalgia treatment introduced in more than fifteen years. The company also markets two FDA-approved migraine products acquired in 2023: Zembrace SymTouch, a low-dose sumatriptan autoinjector with patent protection through 2036, and Tosymra, a sumatriptan nasal spray with patent protection through 2031.

The development pipeline includes multiple clinical and preclinical stage candidates. TNX-102 SL, the proprietary sublingual formulation underlying TONMYA, is being explored in Phase 2 trials for major depressive disorder and acute stress disorder. TNX-4800, a monoclonal antibody targeting Lyme disease prevention, is planned for Phase 2 field and human challenge studies beginning in 2027. TNX-1500, a humanized monoclonal antibody for kidney transplant rejection prevention, is Phase 2-ready. Additional programs include TNX-1300 for cocaine intoxication treatment, TNX-2900 for Prader-Willi syndrome, TNX-801 as a vaccine platform for smallpox and mpox protection, and TNX-4200, a broad-spectrum antiviral supported by a Department of Defense contract potentially worth up to thirty-four million dollars over five years.

Tonix operates research and development facilities including the Research and Development Center in Frederick, Maryland, comprising approximately forty-eight thousand square feet with biosafety level capabilities, and an Advanced Development Center in Dartmouth, Massachusetts spanning approximately forty-five thousand square feet. The company employs approximately ninety sales representatives focused on promoting TONMYA to healthcare providers treating fibromyalgia across rheumatology, primary care, pain management, and neurology practices. Tonix maintains commercial supply agreements and distribution through national wholesalers and specialty distributors.